Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease

Inflammatory Bowel Disease

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Inflamm Bowel Dis.

Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM

doi: 10.1093/ibd/izz001.

Inflammatory Bowel Disease

Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Inflamm Bowel Dis.

Law CCY, Koh D, Bao Y, Jairath V, Narula N

doi: 10.1093/ibd/izaa020.

Inflammatory Bowel Disease

Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis

Clin Gastroenterol Hepatol.

Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ

doi: 10.1016/j.cgh.2019.02.044.

Inflammatory Bowel Disease

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

United European Gastroenterol J.

Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A

doi: 10.1177/2050640620929133.

Inflammatory Bowel Disease

Hormone Therapy for Cancer is a Risk Factor for Relapse of Inflammatory Bowel Diseases

Clin Gastroenterol Hepatol.

Axelrad JE, Bazarbashi A, Zhou J, Castañeda D, Gujral A, Sperling D, Glass J, Agrawal M, Hong S, Lawlor G, Hudesman D, Chang S, Shah S, Yajnik V, Ananthakrishnan A, Khalili H, Colombel JF, Itzkowitz S, New York Crohn’s and Colitis Organization (NYCCO).

doi: 10.1016/j.cgh.

Inflammatory Bowel Disease

Rate of, Risk Factors for, and Interventions to Reduce Hospital Readmission in Patients with Inflammatory Bowel Diseases

Clin Gastroenterol Hepatol.

Nguyen NH, Koola J, Dulai PS, Prokop LJ, Sandborn WJ, Singh S

doi: 10.1016/j.cgh.2019.08.042.

Inflammatory Bowel Disease

No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: a Meta-Analysis

Clin Gastroenterol Hepatol.

Yzet C, Diouf M, Singh S, Brazier F, Turpin J, Nguyen-Khac E, Meynier J, Fumery M

doi: 10.1016/j.cgh.2020.06.071.

Inflammatory Bowel Disease

Risk of bacteremia in hospitalised patients with inflammatory bowel disease: a 9-year cohort study

United European Gastroenterol J.

Goren I, Brom A, Yanai H, Dagan A, Segal G, Israel A

doi: 10.1177/2050640619874524.

Inflammatory Bowel Disease

De-escalation of immunomodulator and biological therapy in inflammatory bowel disease

Lancet Gastroenterol Hepatol.

Chapman TP, Gomes CF, Louis E, Colombel JF, Satsangi J

doi: 10.1016/S2468-1253(19)30186-4.

Related content

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

Hormone Therapy for Cancer is a Risk Factor for Relapse of Inflammatory Bowel Diseases

Rate of, Risk Factors for, and Interventions to Reduce Hospital Readmission in Patients with Inflammatory Bowel Diseases

No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: a Meta-Analysis

Risk of bacteremia in hospitalised patients with inflammatory bowel disease: a 9-year cohort study

De-escalation of immunomodulator and biological therapy in inflammatory bowel disease